Related Experiment Video
Updated: Aug 7, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
1Nevada Cancer Institute, Las Vegas, NV 89135, USA. jward@nvcancer.org
Nature Clinical Practice. Urology
|June 10, 2006
Abstract
No abstract available in PubMed .